APCCC 2021 Conference Coverage

Viewing 1-20 of 28 articles

APCCC 2021: What Can Meta-Analyses, Network Meta-Analyses and Subgroup Analyses Tell Us About Treatment Options: Pearls and Pitfalls

APCCC 2021: DNA Repair Defect Aberrations – What Are the Differences Between Them and What Is the Impact on Patient Management?

APCCC 2021: Contagious Enthusiasm in PSMA-Driven Therapeutics

APCCC 2021: Who Needs Germline Testing – Prostate Cancer

APCCC 2021: Who Needs Germline Testing for Prostate Cancer and What Should Be Tested?

APCCC 2021: Tumor Molecular Testing – Tissue vs Liquid Biopsy

APCCC 2021: Novel and Not So Novel Agents and Where To Place Them in the Treatment Sequence for Prostate Cancer

APCCC 2021: The Role of Somatic Tumor Testing – Implications for Treatment With PARP Inhibitors

APCCC 2021: Best Use of Lutetium-PSMA and Where To Put It in Sequencing Therapies Including Treatment Monitoring

APCCC 2021: Management of Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Review of Panel Responses and Discussion

APCCC 2021: Informing Treatment Decisions in mHSPC – Molecular Markers

APCCC 2021: Do Different Subgroup of Patients Need Different Treatments?

APCCC 2021: Are There Still Patients Where Treatment with ADT Alone Is Still Appropriate?

APCCC 2021: PSMA –Based Imaging: Navigating the Pitfalls of the Different Tracers

APCCC 2021: The Background of PSMA in Prostate Cancer

APCCC 2021: What Is the Evidence for “Triplet Therapy”?

APCCC 2021: Somatic Testing – When and What? (Including Mismatch Repair Evaluation)

APCCC 2021: PSMA PET: For Staging To Improve Clinical Outcomes

APCCC 2021: Are There Still Patients Where Treatment with ADT Alone Is Appropriate?

APCCC 2021: Summary of Panel Responses Regarding Tumor Molecular Testing

1
2

email news signup